A recent meta-analysis in patients with T2DM demonstrated that SGLT2 inhibition was associated with decreased circulating leptin (121), and we recently found that SGLT2 inhibition decreases plasma leptin in HAF rats (97). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.